Compare TWI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TWI | CTNM |
|---|---|---|
| Founded | 1890 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 691.3M | 575.3M |
| IPO Year | 1997 | 2024 |
| Metric | TWI | CTNM |
|---|---|---|
| Price | $9.92 | $15.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $11.50 | ★ $18.60 |
| AVG Volume (30 Days) | ★ 551.9K | 197.4K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.93 | $3.35 |
| 52 Week High | $11.70 | $16.33 |
| Indicator | TWI | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 59.89 |
| Support Level | $8.24 | $10.17 |
| Resistance Level | $10.03 | $16.01 |
| Average True Range (ATR) | 0.50 | 0.90 |
| MACD | -0.16 | -0.06 |
| Stochastic Oscillator | 19.47 | 66.40 |
Titan International Inc is a manufacturer of wheels, tires, wheel and tire assemblies, and undercarriage systems and components for off-highway vehicles. The company operates through three segments namely Agricultural, Earthmoving/Construction, and Consumer. Geographically, business of the group can be seen in the United States, Europe / CIS, Latin America and Other international. Titan derives majority of the revenue from Agricultural segment which manufacture various agricultural equipment, including tractors, combines, plows, planters and irrigation equipment, and are sold directly to original equipment manufacturers and to the aftermarket through independent distributors, equipment dealers and Titan's own distribution centers.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.